Dyadic International, Inc. (DYAI) is a Biotechnology company in the Healthcare sector, currently trading at $0.87. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DYAI = $3 (+244.8% upside).
Valuation: DYAI trades at a trailing Price-to-Earnings (P/E) of -4.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Financials: revenue is $3M, +2.6%/yr average growth. Net income is $7M (loss), growing at +5.1%/yr. Net profit margin is -238.3% (negative). Gross margin is 24.9% (-2.6 pp trend).
Balance sheet: total debt is $5M against $1M equity (Debt-to-Equity (D/E) ratio 4.11, leveraged). Current ratio is 2.68 (strong liquidity). Debt-to-assets is 50.9%. Total assets: $10M.
Analyst outlook: 1 / 2 analysts rate DYAI as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 55/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 20/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
